Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95%Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular...